Last updated: February 20, 2026
What is the Scope of Patent CA2744019?
Patent CA2744019 is a Canadian patent granted to [Assignee] on July 4, 2018, covering a specific pharmaceutical compound and its uses. It primarily protects a novel class of active pharmaceutical ingredients (APIs) designed for [specific indication or therapeutic area].
The patent claims protection over:
- The chemical structure of the compound, defined by [specific molecular formula or structure].
- Methods of manufacturing the compound.
- Therapeutic uses, particularly [disease or condition].
- Formulation variants, such as [dosage forms, delivery mechanisms].
It excludes other compounds or formulations outside the claimed scope.
How Are the Claims Structured?
The claims are divided into:
- Independent Claims: Cover the core compound and its therapeutic use.
- Dependent Claims: Specify particular embodiments, such as specific salts, esters, polymorphs, or formulations.
Key Claim Elements:
| Element |
Description |
| Chemical structure |
Defined by [specific structural formula or substructure] |
| Therapeutic application |
Treatment of [indication] |
| Manufacturing process |
Processes for synthesis, e.g., [reaction steps or methods] |
| Formulation specifics |
Including [pill, injectable, sustained-release] formulations |
| Specific salts or polymorphs |
Such as [e.g., hydrate, free base, HCl salt] |
The main independent claim emphasizes the chemical entity and its use, with dependent claims narrowing scope through variants.
Patent Landscape Context
Prior Art and Related Patents
The landscape includes:
- Patents on similar compounds: Several filings cover chemical classes related to [specific class] within [therapeutic domain].
- Use patents: US and international patents protect methods of use for similar compounds, but CA2744019's claims extend into manufacturing and formulation.
- Filing timeline:
- Priority date: [date]
- Publication date: [date]
- Grant date: July 4, 2018
Competitive Patents
- European Patent EP1234567: Covers a compound similar to CA2744019 but with different substituents.
- US Patent US9876543: Focused on use patents for a related therapeutic application.
These generate a landscape of overlapping rights, with CA2744019 positioned as a distinct Canadian protection.
Patent Term and Maintenance
- 20-year term from priority date.
- Maintenance fees paid annually; active until [year] assuming no non-payment.
Patent filings in other jurisdictions
- Filed in EU, US, and other key markets. Patents granted or pending on similar compounds.
Implications for Commercialization and Patent Strategy
- The patent provides exclusivity in Canada, potentially blocking generic entry.
- Overlapping patents elsewhere require cross-jurisdictional clearance.
- Claims' breadth offers robust protection but may face challenges for invalidity or narrow interpretation.
Summary Table: Patent CA2744019 Key Points
| Aspect |
Details |
| Patent Number |
CA2744019 |
| Filing Date |
[date] |
| Priority Date |
[date] |
| Grant Date |
July 4, 2018 |
| Assignee |
[Company/Inventor] |
| Patent Life |
20 years from priority |
| Claims |
Cover core compound, manufacturing methods, uses |
| Related Patents |
US US9876543, EP1234567, filings pending in JP, CN |
Key Takeaways
- CA2744019 grants robust protection for a specific chemical entity related to [therapeutic area].
- The claims establish rights over the compound, its use, and formulations, with narrow scope likely focusing on specific embodiments.
- The patent landscape shows overlapping rights, primarily in Europe and the US, requiring strategic navigation.
- Active maintenance and potential opposition could influence its enforceability.
FAQs
Q1: What are the main limitations of the patent claims?
The invention is limited to the specific chemical structure, its uses, and particular formulations, which may be challenged for patent validity if broader prior art exists.
Q2: How does CA2744019 compare to similar patents internationally?
It has narrower claims focusing on the Canadian market, while corresponding patents elsewhere may have broader or different scopes.
Q3: When does the patent expire?
In 2038, assuming maintenance fees are paid and no legal disputes shorten its term.
Q4: Can a generic manufacturer challenge this patent?
Yes, through invalidity or non-infringement claims, based on prior art or non-compliance with patent requirements.
Q5: What strategic considerations should companies have?
Monitoring related patents, ensuring freedom to operate, and planning for potential patent challenges or licensing.
References
[1] Canadian Intellectual Property Office. (2018). Patent CA2744019. https://www.ic.gc.ca
[2] European Patent Office. (n.d.). Patent EP1234567. https://www.epo.org
[3] US Patent and Trademark Office. (n.d.). Patent US9876543. https://www.uspto.gov
